Objectives: This study aims to investigate the correlation between serum anti-heat-shock protein 70 (anti-HSP 70) levels, serum paraoxonase (PON) levels and prognosis of idiopathic sudden sensorineural hearing loss (ISSHL).
Sudden hearing loss is a sensorineural hearing loss (SHL) exceeding 30 dB over three contiguous pure-tone frequencies occurring within three days. The incidence of SHL in the population is 5-20/100,000. It generally occurs between the ages of 30 and 60 years, 90% is unilateral, and it has various causes. Nevertheless, no identifiable cause is detected in 80-90% of patients; this is known as idiopathic sudden sensorineural hearing loss (ISSHL). [1, 2] Generally, the prognosis is bad in patients with advanced age, bilateral and total hearing loss, objective vestibular symptoms, vascular disorders, and delayed treatment. If the hearing loss curve decreases from low-to highpitched sound in the audiogram in SHL, it is called a rising curve and has a good prognosis. [1] However, no serum prognostic marker has been identified for ISSHL.
In 1990, Harris and Sharp [3] discovered antibodies against a 68-kDa protein derived from inner ear extracts of cattle in the serum of SHL patients. Subsequent studies examined the role of these anti-68-kDa antibodies in SHL and Ménière's disease. The antibody, which was produced in response to an infectious agent, can cross-react with human heat-shock protein 70 (HSP70), and can trigger an autoimmune reaction in human target organs, as in the excessive secretions caused by chronic inflammation in patients with Ménière's disease and hearing loss. [4] Although many studies have examined serum anti-HSP antibodies in the majority of inner ear diseases, few have investigated the relationship between the anti-HSP70 level in ISSHL patients and prognosis.
It has been postulated that human serum paraoxonase (PON) is related to high-density lipoprotein (HDL), and that it has an antioxidant function. Experimental studies have shown relationships between PON and the HDLs apolipoprotein-A1 (Apo-A1) and apolipoprotein J (Apo-J)/clusterin. [5] [6] [7] [8] [9] [10] [11] Paraoxonase is thought to exert its antioxidant effect by protecting low density lipoprotein-K (LDL-K) from the oxidation induced by copper ions and free radicals. [6, [7] [8] [9] [10] [11] [12] One study found an association between a PON2 gene polymorphism and SHL and postulated that it could represent a marker of susceptibility to noise-induced hearing loss. [13] As mentioned, few studies have evaluated the relationship between anti-HSP70 levels and the prognosis of ISSHL patients. In addition, no study has directly investigated the correlation between serum PON activity and hearing loss. Therefore, we investigated the correlations between serum anti-HSP70 and PON levels and the prognosis of ISSHL. Detailed histories were obtained from all patients with a diagnosis of ISSHL and the control volunteers. Detailed ear, nose, throat, and systemic examinations were performed. The routine biochemical parameters, hemogram, prothrombin time (PT), and active partial thromboplastin time (aPTT) were measured. Patients seen within seven days of the onset of hearing loss with normal preprandial blood biochemistry were included in the study. Patients who had previously suffered from hearing loss, had any additional systemic diseases, any ear disease, retrocochlear pathology detected by temporal bone magnetic resonance imaging (MRI), coagulation disorders detected when the serum PT and aPTT were examined, and immunoglobulin M (IgM) for viruses (including CMV, roseola, rubella, chicken pox, HSV-1, HSV-2, parainfluenza, influenza A and B, EBV, or mumps) were excluded.
PATIENTS AND METHODS

Fifty
The diagnosis of ISSHL was established as a hearing loss ≥30 dB detected at 250, 500, 1000, 2000, 4000, and 6000 Hz on pure-tone audiometry. Recovery of the hearing thresholds was evaluated 10 days after initiating treatment and was classified in accordance with Siegel's classification for the standardization of the recovery of patients with hearing loss, as follows: [14] Category I: Complete recovery;
Category II: Despite a recovery exceeding 15 dB, the patient does not have a normal hearing threshold, but has a pure-tone audiometry average better than 45 dB (partial recovery);
Category III: Despite a recovery exceeding 15 dB, the patient's pure-tone audiometry average is worse than 45 dB (partial recovery);
Category IV: The recovery is less than 15 dB or there is no recovery of the hearing thresholds (no recovery).
Corticosteroid treatment was initiated after the diagnosis of ISSHL, and serum samples were obtained from the patients. The patients were administered 1 mg/kg prednisone (Prednol tablets, Mustafa Nevzat Drug Industry, Turkey) orally, and the dose was reduced by 8 mg per day. While on the corticosteroid, the patients were administered the proton pump inhibitor lansoprazole (Lanzedin, Biofarma Drug Industry, Turkey) 2x30 mg orally. Parenteral 76% sodium amidotrizoate 2x1/2 ampoules (Urografin, Bayer Turkish Chemistry Drug Industry, Turkey) was infused intravenously for five days. Oral vitamin B1 (2x250 mg thiamine hydrochloride) and B6 (250 mg pyridoxine hydrochloride; Nerox B tablet, Abdi İbrahim Pharmaceutical Company) were given for three months. Carbogen therapy (5% CO 2 + 95% O 2 ) was applied for 10 days, four times per day, for 30 min each via inhalation. The antiviral brivudine 125 mg orally (Zostex, Ufsa Drug Industry, Turkey) was administered for seven days and the microcirculation regulating agent trimetazidine 3x20 mg (Vastarel, Servier Drug Industry, Turkey) was added for three months.
Blood samples (4 ml) were collected in anticoagulant-free tubes from the patients before the treatment started and on the tenth day of treatment, and once from the healthy controls. The samples were centrifuged for 10 min at 4000 rpm, +4 °C and the serum was stored at -80 °C until the PON and anti-HSP70 levels were determined. The serum PON activity was measured using the method of Eckerson et al., [15] which is based on the spectrophotometric measurement of the activity of 4-nitrophenol produced via enzymatic hydrolysis with the addition of 1 mol/L NaCl at a wavelength of 412 nm (Techcomp 8500 II UV/vis, Techcomp, China). An ELISA kit (Stressgen, catalogue no: EKS-750, Ann Arbor, USA) was used to assay anti-HSP70. The anti-HSP70 IgG, IgA, and IgM (total) levels were determined spectrophotometrically.
For statistical analysis, Student's t-test was performed using the SPSS version 12.0 for Windows software program (SPSS Inc., Chicago, IL, USA) A value of p<0.05 was taken to indicate statistical significance.
RESULTS
In the study group, 13 patients first visited our clinic within three days of their hearing loss, and the other 12 patients visited 4-7 days after their hearing losses. Their treatments were started on the first visit. When the frequency-specific hearing thresholds before and after treatment were compared, significant recovery was observed Pre-treatment serum PON levels were significantly (p<0.05) higher in the study group than in controls. Although the pre-treatment serum anti-HSP70 levels were higher in the study group, the difference was not significant (p>0.05) ( Table 1 ). The post-treatment serum PON levels were significantly (p<0.05) higher in the study group than in the controls. Although the posttreatment serum anti-HSP70 levels were lower in the study group than the controls, the difference was not significant (p>0.05) ( Table 2 ).
In the ISSHL patients, there was no significant (p>0.05) difference between the pre-and posttreatment serum PON levels, but a significant (p<0.05) difference was identified between the pre-and post-treatment serum anti-HSP70 levels (Table 3 ). In the ISSHL patients with either complete or partial recovery, the post-treatment serum anti-HSP70 levels were significantly (p<0.05) lower than the pre-treatment levels. The decrease was not significant in the patients who did not recover (Table 4) . Conversely, the pretreatment serum PON levels were lower than the post-treatment serum PON levels in the patients who recovered, but were higher in those who did not recover; however, these differences were not significant (p>0.05) ( Table 5) .
DISCUSSION
Idiopathic sudden sensorineural hearing loss is an otological emergency. Despite intensive investigation of the physiopathology and histopathology of SHL, the etiology is not understood completely. The treatment of ISSHL is based on its etiology. In ISSHL, treatment has no superiority to spontaneous recovery which is observed in 60-65% of patients, even without Table 4 . Mean anti-heat-shock protein 70 levels of patients who did and did not recover before and after treatment treatment, in the first two weeks after disease onset. [16] For the last 50 years, ISSHL has been thought to have an autoimmune origin. In animal studies, the cochlea secretes HSP70 upon ototoxic stimulation. [17] Mathews et al. [18] found that ISSHL patients possessed antibody against HSP70. Loveman et al. [19] detected anti-HSP70 in the serum of 27 of 30 patients (90%) with ISSHL. Although the existence of serum anti-HSP70 antibody has been investigated in most inner ear diseases, few studies have evaluated the relationship between the anti-HSP70 level and the prognosis of patients with ISSHL.
Similarly, a PON2 gene polymorphism may be associated with SHL and could represent a marker of susceptibility to noise-induced hearing loss. [13] However, no study has examined the serum PON levels of patients with ISSHL. We found no significant difference between the pretreatment serum anti-HSP70 levels of the study and control groups. However, in the study group, the pre-and post-treatment serum anti-HSP70 levels differed significantly. In addition, serum anti-HSP70 levels were significantly lower in patients who recovered (either complete or partial recovery) than those who did not.
Süslü et al. [20] investigated anti-HSP70, tumor necrosis factor-alpha (TNF-a), and antinuclear antibody (ANA) levels, and erythrocyte sedimentation rate (ESR), in ISSHL and found no increase in anti-HSP70 levels in the study group compared to controls, but significant increases in ANA and ESR and a decrease in TNF-a levels. Park et al. [21] reported a significant difference in the anti-HSP70 levels of patients compared to a control group before treatment for sudden hearing loss. Similarly, Gross et al. [22] detected anti-HSP70 antibodies in 60 of 63 SHL patients. In our study, there was no significant difference between the pre-treatment serum anti-HSP70 levels of the study group and those of the controls, similar to the findings of Süslü et al. [20] Paraoxonase exists in many tissues, including the liver, kidneys, small intestine, and in serum. [6, 23] Non-genetic factors, such as diet, acute-phase reactants, pregnancy, hormones, smoking, and simvastatin treatment, can modulate serum PON levels. [24] Moreover, PON activity decreases with increased age. [25] In our study, the pre-treatment serum PON levels of the ISSHL patients were significantly (p<0.05) higher than those of controls. The pre-treatment serum PON levels were high in recovered (either complete or partial recovery) patients after treatment. In the patients who did not recover, the post-treatment serum PON levels were lower than the pre-treatment levels. However, these differences were not significant (p>0.05).
Conclusion
When the ISSHL patients were subdivided into groups that did (either complete or partial recovery) or did not (no recovery) recover, the pre-treatment serum anti-HSP70 levels of the recovered patients were higher than the posttreatment levels. Conversely, the pre-treatment serum PON levels of the recovered patients were lower than the post-treatment levels. An increase in the post-treatment serum PON levels suggests a good prognosis; moreover, the prognosis of ISSHL might be better in those with higher pre-treatment serum anti-HSP70 levels compared to those post-treatment. Therefore, serum anti-HSP70 and PON levels might represent novel prognostic markers for ISSHL patients; however more comprehensive studies of this topic are needed.
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